Puma Biotechnology (NASDAQ:PBYI) Releases Quarterly Earnings Results, Beats Estimates By $0.09 EPS

Puma Biotechnology (NASDAQ:PBYI) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.09, FiscalAI reports. Puma Biotechnology had a return on equity of 20.81% and a net margin of 10.69%.The firm had revenue of $44.81 million during the quarter, compared to analyst estimates of $42.00 million.

Here are the key takeaways from Puma Biotechnology’s conference call:

• ALISCA?Lung1 interim: higher?dose alisertib (60 mg) showed a median PFS of 4.2 months versus 1.7 months at 50 mg and activity is enriched in c?MYC?high tumors; dose escalation to 70 mg and a combination ALISCA?Lung2 (with paclitaxel) are planned for H2 2026.
• ALISCA?Breast1 interim: alisertib plus endocrine therapy showed median PFS ~5.45–5.59 months in the 40–50 mg arms with stronger efficacy in biomarker subgroups (PIK3CA wild?type, ESR1?mutant and high c?MYC); enrollment will be expanded to biomarker?focused cohorts and updated data are expected H2 2026.
• Financials & guidance: raised FY2026 net NERLYNX product revenue guidance to $202–206M, expects FY net income of $16–19M, and is now debt?free after the final Athyrium payment with ~$101.5M in cash/marketable securities as of 3/31/2026.
• Q1 commercial softness: Q1 net product revenue fell to $42.0M (2,328 ex?factory bottles, down ~29% QoQ) driven in part by an estimated ~439?bottle inventory drawdown at specialty channels; TRXs were down ~4% QoQ and demand declined ~6% QoQ despite higher NRX and enrollment trends.

Puma Biotechnology Stock Up 3.2%

Shares of Puma Biotechnology stock traded up $0.23 during trading hours on Friday, reaching $7.49. 755,011 shares of the company’s stock were exchanged, compared to its average volume of 267,164. Puma Biotechnology has a 1 year low of $2.85 and a 1 year high of $7.90. The company has a market capitalization of $381.17 million, a P/E ratio of 15.60 and a beta of 1.24. The business has a fifty day moving average of $6.81 and a two-hundred day moving average of $6.19.

Institutional Investors Weigh In On Puma Biotechnology

A number of large investors have recently made changes to their positions in PBYI. Russell Investments Group Ltd. grew its position in shares of Puma Biotechnology by 4,823,365.0% in the third quarter. Russell Investments Group Ltd. now owns 964,693 shares of the biopharmaceutical company’s stock valued at $5,123,000 after purchasing an additional 964,673 shares in the last quarter. Goldman Sachs Group Inc. grew its position in shares of Puma Biotechnology by 238.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 793,962 shares of the biopharmaceutical company’s stock valued at $4,724,000 after purchasing an additional 559,345 shares in the last quarter. AQR Capital Management LLC grew its position in shares of Puma Biotechnology by 410.1% in the fourth quarter. AQR Capital Management LLC now owns 666,605 shares of the biopharmaceutical company’s stock valued at $3,966,000 after purchasing an additional 535,933 shares in the last quarter. Bridgeway Capital Management LLC grew its position in shares of Puma Biotechnology by 78.4% in the fourth quarter. Bridgeway Capital Management LLC now owns 773,485 shares of the biopharmaceutical company’s stock valued at $4,602,000 after purchasing an additional 339,924 shares in the last quarter. Finally, O Shaughnessy Asset Management LLC grew its position in shares of Puma Biotechnology by 35.3% in the fourth quarter. O Shaughnessy Asset Management LLC now owns 1,120,329 shares of the biopharmaceutical company’s stock valued at $6,666,000 after purchasing an additional 292,108 shares in the last quarter. 61.29% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. Wall Street Zen upgraded Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 21st. Weiss Ratings restated a “hold (c+)” rating on shares of Puma Biotechnology in a research note on Tuesday, April 21st. One equities research analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the company presently has an average rating of “Hold”.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a late?stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.

The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small?molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early?stage HER2-positive breast cancer.